Rimonabant
Code | Size | Price |
---|
TAR-T1519L-10mg | 10mg | £104.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1519L-1mL | 1 mL * 10 mM (in DMSO) | £114.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1519L-25mg | 25mg | £137.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1519L-50mg | 50mg | £177.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1519L-100mg | 100mg | £229.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Rimonabant is an inverse agonist for the cannabinoid receptor CB1. It is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. Its main avenue of effect is a reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States.
CAS:
168273-06-1
Formula:
C22H21Cl3N4O
Molecular Weight:
463.79
Pathway:
Microbiology/Virology; GPCR/G Protein; Metabolism
Purity:
0.9991
SMILES:
Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1
Target:
Cannabinoid Receptor; Antibacterial; Acyltransferase
References
1. Chu CM, et al, Org Biomol Chem, 2008, 6(18), 3399-3407
2. Netherland C, et al, Biochem Biophys Res Commun, 2010, 398(4), 671-676.
3. Rinaldi-Carmona M, et al, FEBS Lett, 1994, 350(2-3), 240-244.
4. Santoro A, et al, Int J Cancer, 2009, 125(5), 1996-12003.
5. Schafer A, et al, Br J Pharmacol, 2008, 154(5), 1047-1054.